Newer HRT regimens

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 10, 1997, Pages 1109-1115

  Sturdee, David W ^a  

^a SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ESTRACOMBI; ESTRADIOL; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORETHISTERONE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTRONE; FEMSEVEN; GESTAGEN; HORMONIA; IMPROVERA; MEDROXYPROGESTERONE ACETATE PLUS ESTRADIOL; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; TRIDESTRA; UNCLASSIFIED DRUG;

ADULT; CARDIOVASCULAR DISEASE; DRUG EFFICACY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; DRUG COMBINATIONS; DRUG IMPLANTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LONG-TERM CARE; PROGESTINS; UTERINE HEMORRHAGE;

EID: 0030884301     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb10932.x     Document Type: Review

References (70)

1. Richardson RG. The menopause—a neglected crisis. Queensborough, Abbot Laboratories, 1973.
2. Novak E. The management of the menopause. Am J Obstet Gynecol 1940; 40: 589–595.
3. Torgerson DJ, Donaldson C, Russell IT, Reid DM. Hormone replace- ment therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol 1995; 59: 57–60.
4. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173 (3 Suppl): 982–989.
5. Longcope C, Gorbach S, Goldin B et al. The metabolism of estradiol: oral compared to intravenous administration. J Steroid Biochem 1985; 23: 1065–1070.
6. Townsend PT, Dyer GI, Young O, Whitehead Ml, Collins WP. The absorption and metabolism of oral oestradiol, oestrone and oestriol. Br J Obstet Gynaecol 1981; 88: 846–852.
7. Mashchak CA, Lobo RA, Dozono-Takano R et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511–518.
8. Warren RJ, Fotherby K. Plasma levels of ethinyloestradiol after administration of ethinyloestradiol or mestranol to human subjects. J Endocrinol 1973; 59: 369–370.
9. Horsman A, Gallagher JC, Simpson M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 1977; 2: 789–792.
10. Al-Azzawi F, Hart DM, Lindsay R. Long-term effects of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. BMJ 1987; 294: 1261–1262.
11. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432–437.
12. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. J Fertil 1993; 38 Suppl 1: 30–35.
13. The Writing Group for the PEP1 Trial. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199–208.
14. Basdevant A, De Lignieres B, Guy-Grand B. Differential lipemic and hormonal responses to oral and parenteral l74bT-estradiol in postmenopausal women. Am J Obstet Gynecol 1983; 147: 77–81.
15. Alkjaersig N, Fletcher AP, De Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration J Lab Clin Med 1988; 111: 224–228.
16. Fox J, George AJ, Newton JR, Parsons AD et al. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55–64.
17. Chetkowski RJ, Meldrum DR, Steingold KA et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615–1620.
18. Poller L, Thomson JM, Coope J. Conjugated equine oestrogens and blood clotting: a follow up report. BMJ 1977; 1: 935–936.
19. Medical Research Council’s GP Research Framework. Randomised comparison of oestrogen versus oestrogen and progestogen HRT in women with hysterectomy. BMJ 1996; 312: 473–478.
20. Laufer LR, De Fazio JL, Lu JKH et al. Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 1983; 146: 533–540.
21. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Safety 1993; 9: 365–379.
22. The Transdermal HRT Investigators Group. A randomised study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. IntJ Fertil 1993; 38: 5–11.
23. Sentrakul P, Chompootaweek S, Sintupak S et al. Adverse skin reactions to transdermal oestradiol in tropical climate. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women. Maturitas 1991; 13: 151–154.
24. Dupont A, Dupont P, Cusan L, Tremblay M et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991; 13: 297–311.
25. Bishop PMF. A clinical experiment in oestrogen therapy. BMJ 1938; 1: 939–941.
26. Greenblatt RB, Suran RR. Indications for hormonal pellets in the therapy of endocrine and gynecological disorders. Am J Obstet Gynecol 1949; 57: 294–301.
27. Schleyer-Saunders E. The management of the menopause. Medical Press 1960; 244: 337.
28. Studd JWW, Holland EFN, Leather AT, Smith RNJ. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. BrJ Obstet Gynaecol 1994; 101: 787–791.
29. Gangar KF, Cust MP, Whitehead MI. Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. BMJ 1989; 299: 601–602.
30. Gangar KF, Fraser D, Whitehead MI, Cust MP. Prolonged endome-trial stimulation associated with oestradiol implants. BMJ 1990; 300: 436–38.
31. Owen EJ, Siddle NC, McGarrigle HT, Pugh MA. 25 mg oestradiol implants: the dosage of first choice for subcutaneous oestrogen replacement therapy Br J Obstet Gynaecol 1992; 99: 671–675.
32. Naessen T, Persson I, Thor L, Mallmin H, Ljunghal S, Bergstrom R. Maintained bone density at advanced ages after long term treatment with low dose oestradiol implants. Br J Obstet Gynaecol 1993; 100: 454–459.
33. Holland EF, Leather AT, Studd JWW. The effect of 25 mg percutaneous oestradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994; 83: 43–46.
34. Studd JWW. Hormone implantation. The Diplomate 1996; 3: 19–24.
35. Garnett T, Studd JWW, Henderson A, Watson N, Savvas M, Leather AT. Hormone implants and tachyphylaxis. Br J Obstet Gynaecol 1990; 97: 917–921.
36. Pearce J, Horton K, Blake F, Barlow DH et al. Psychological effect of continuation versus discontinuation of HRT by oestrogen implants; a placebo controlled study. J Psychosomat Res 1997; 42: 177–186.
37. Studd JWW, Chakravarti S, Collins WP et al. Oestradiol and testosterone implants in the treatment of psychosexual problems in the postmenopausal woman. Br J Obstet Gynaecol 1977; 84: 314–315.
38. Brincat M, Magos A, Studd JWW. Subcutaneous hormone implants for the control of climacteric symptoms: a prospective study. Lancet 1984; 1: 16–18.
39. Dow MGT, Hart DM, Forrest CA. Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study. Br J Obstet Gynaecol 1983; 90: 361–366.
40. Sturdee DW, Barlow DH, Ulrich LG, Wells M et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen progestogen replacement therapy Lancet 1994; 344: 979–982.
41. Persson I, Adami H-O, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147–151.
42. Voigt LF, Weiss NS, Chu J, Daling JR et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277.
43. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic prog- estagen therapy in postmenopausal women. Lancet 1997; 349: 458–61.
44. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305: 1599–1605.
45. Siddle NC, Jesinger DK, Whitehead MI, Turner P, Lewis B, Prescott P. Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990; 97: 1093–1100.
46. Psaty BM, Heckbert SR, Atkins D et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–1339.
47. Flowers CE, Wilborn WH, Hyde BM. Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin. Obstet Gynecol 1983; 61: 135–143.
48. Ryder TA, Mobberley MA, Whitehead MI. The endometrial nucleolar channel system as an indication of progestin potency in HRT. Maturitas 1995; 22: 31–36.
49. Kemp JF, Fryer JA, Baber RJ. An alternative regimen of hormone replacement therapy to improve patient compliance. Aust NZ J Obstet Gynaecol 1989; 29: 66–69.
50. David A, Czernobilsky B, Weisglass L. Long cyclic hormonal cycle therapy in postmenopausal women In: Berg G, Hammar M. The Modern Management of the Menopause. Proceedings of VII International Congress on the Menopause. London: Parthenon, 1994: 463–470.
51. Ettinger B, Selby J, Citron JT, Vangessel A et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693–700.
52. Hirvonen E, Salmi T, Puolakka J, Heikkinen J et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen Maturitas 1995; 21: 39–44.
53. O’Bryan-Tear G. Tridestra—a new 3-monthly sequential hormone replacement treatment. J Obstet Gynaecol; 1996; 16 Suppl 1: 1–3.
54. Staland B. Continuous treatment with a combination of estrogen and gestagen—a way of avoiding endometrial stimulation. Acta Obstet Gynecol Scand 1982; 130 Suppl: 29–35.
55. Mattsson L, Cullberg G, Samsioe G. Evaluation of a continuous combined oestrogen/progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95–102.
56. Magos A, Brincat M, Studd JWW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhoea and endometrial atrophy with continuous oral estrogens and progestin therapy in post menopausal women. Obstet Gynecol 1985; 65: 496–99.
57. Benedek-Jaszmann LJ. Long term placebo-controlled efficacy and safety study of ORG OD14 in climacteric women. Maturitas 1987; 9 Suppl 1: 25–33.
58. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endome- trial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestogenic activity ratios of steroidal drugs. J Steroid Biockem Mol Biol 1993; 45: 345–351.
59. Rymer J, Fogelman I, Chapman MO. The incidence of vaginal bleeding with tibolone. Br J Obstet Gynaecol 1994; 101: 53–56.
60. Hawthorn RJS, Spowart K, Walsh D, McKay Hart D. The endome-trial status of women on long term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991; 98: 939–942.
61. Sturdee DW. Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil 1996; 41: 22–28.
62. Wells M. Endometrial response to continuous combined HRT. 8th International Congress on the Menopause; Sydney, Australia; 1996: Abstract no. 539.
63. Doren M, Reuther C, Minne HW, Schneider HPG. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995; 173: 1446–1451.
64. Andersson K, Mattsson L-A, Rybo G, Stadberg G. Intrauterine release of levonorgestrel—a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963–967.
65. Randaskoski TH, Lahti El, Kauppila AJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114–119.
66. Barlow DH, Cardozo LD, Francis RM, Griffin M et al. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol 1997; 104: 87–91.
67. Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991; 14: 23–31.
68. Schiff I, Tulchinsky D, Ryan KJ. Vaginal absorption of estrone and 17β-estradiol. Fertil Steril 1977; 28: 1063–1067.
69. Rigg LA, Hermann H, Yen SC. Absorption of estrogen from vaginal creams. N Engl J Med 1978; 298: 195–198.
70. Smith P, Heimer G, Lindskog M, Ulmsten U. Estradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993; 16: 145–154.